Company: PHAT
Filing Date: 2025-04-23
Form Type: DEF 14A
Source: 0000950170-25-057326
Chunk: 59

Company: Phathom Pharmaceuticals, Inc.
Filing Date: 2025-04-23
Form: DEF 14A
Chunk 59
---
7.96 |     |                      |         — |     |    |
| 2019 Incentive Award Plan                                |     |                   | 5,084,412 |     | $                 | 10.78 |     |                      | 1,578,888 |     |    |
| 2019 Employee Stock Purchase Plan                        |     |                   |         — |     |                   |     — |     |            1,177,618 |           |     | -1 |
| Total equity compensation plans approved by stockholders |     |                   | 6,157,532 |     | $                 | 10.29 |     |                      | 2,756,506 |     |    |
| Equity compensation plans not approved by stockholders   |     |                   |         — |     |                   |     — |     |                      |         — |     |    |

(1) With respect to the 2019 Employee Stock Purchase Plan, includes 1,177,618 shares available for issuance under such plan as of December 31, 2024 (of which all 1,177,618 shares were eligible for issuance pursuant to the offering period in effect on such date). Delinquent Sec tion 16(a) Reports Section 16(a) of the Securities Exchange Act of 1934 requires our directors, officers and beneficial owners of 10% or more of our common shares to file reports with the SEC. We assist our directors and officers by monitoring transactions and completing and filing these reports on their behalf. Based on our records and other information, we believe that all reports that were required to be filed under Section 16(a) during 2024, were timely filed, except the Form 4 filed on March 21, 2025 for Asit Parikh was not filed on a timely basis.

<div align='center'>43

CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS</div>

We describe below the transactions and series of similar transactions, since January 1, 2024 to which we were a party or will be a party, in which:

the amounts involved exceeded or will exceed $120,000; and

any of our directors, executive officers or, to our knowledge, beneficial owners of more than 5% of our capital stock or any member of their immediate family had or will have a direct or indirect material interest.

PCI Pharma Services

Frazier is a principal stockholder in PCI Pharma Services, or PCI. In the